{"pmid":32266501,"title":"Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.","text":["Double Jeopardy: Methamphetamine Use and HIV as Risk Factors for COVID-19.","AIDS Behav","Carrico, Adam W","Horvath, Keith J","Grov, Christian","Moskowitz, Judith T","Pahwa, Savita","Pallikkuth, Suresh","Hirshfield, Sabina","32266501"],"journal":"AIDS Behav","authors":["Carrico, Adam W","Horvath, Keith J","Grov, Christian","Moskowitz, Judith T","Pahwa, Savita","Pallikkuth, Suresh","Hirshfield, Sabina"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32266501","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10461-020-02854-w","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["Methamphetamine"],"_version_":1663609715789135874,"score":7.9164424,"similar":[{"pmid":32220278,"title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","text":["Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","Lancet","Ritchie, Andrew I","Singanayagam, Aran","32220278"],"journal":"Lancet","authors":["Ritchie, Andrew I","Singanayagam, Aran"],"date":"2020-03-30T11:00:00Z","year":2020,"_id":"32220278","week":"202014|Mar 30 - Apr 05","doi":"10.1016/S0140-6736(20)30691-7","link_comment_for":"32192578","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135138410497,"score":77.4055},{"pmid":32216698,"title":"Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility.","text":["Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility.","Patients with hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease, and kidney dysfunction have worse clinical outcomes when infected with SARS-CoV-2, for unknown reasons. The purpose of this review is to summarize the evidence for the existence of elevated plasmin(ogen) in COVID-19 patients with these comorbid conditions. Plasmin, and other proteases, may cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe patients. The plasmin(ogen) system may prove a promising therapeutic target for combating COVID-19.","Physiol Rev","Ji, Hong-Long","Zhao, Runzhen","Matalon, Sadis","Matthay, Michael A","32216698"],"abstract":["Patients with hypertension, diabetes, coronary heart disease, cerebrovascular illness, chronic obstructive pulmonary disease, and kidney dysfunction have worse clinical outcomes when infected with SARS-CoV-2, for unknown reasons. The purpose of this review is to summarize the evidence for the existence of elevated plasmin(ogen) in COVID-19 patients with these comorbid conditions. Plasmin, and other proteases, may cleave a newly inserted furin site in the S protein of SARS-CoV-2, extracellularly, which increases its infectivity and virulence. Hyperfibrinolysis associated with plasmin leads to elevated D-dimer in severe patients. The plasmin(ogen) system may prove a promising therapeutic target for combating COVID-19."],"journal":"Physiol Rev","authors":["Ji, Hong-Long","Zhao, Runzhen","Matalon, Sadis","Matthay, Michael A"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32216698","week":"202013|Mar 23 - Mar 29","doi":"10.1152/physrev.00013.2020","keywords":["COVID-19","SARS-CoV-2","comorbidity","fibrinolysis","plasmin(ogen)"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135071301634,"score":65.34258},{"pmid":32275190,"title":"Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carry a Moderately Increased Risk of Death.","text":["Chronic Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers Is High Among Intensive Care Unit Patients With Non-COVID-19 Sepsis but Carry a Moderately Increased Risk of Death.","Hypertension","Sunden-Cullberg, Jonas","32275190"],"journal":"Hypertension","authors":["Sunden-Cullberg, Jonas"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275190","week":"202015|Apr 06 - Apr 12","doi":"10.1161/HYPERTENSIONAHA.120.15178","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663712077958610944,"score":47.875443},{"pmid":32251717,"title":"Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome.","text":["Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome.","Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We describe the potential impact of viral load and therapy timing towards improving the outcome of IL-6 antagonism and other immunomodulatory therapies.","Autoimmun Rev","McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie","32251717"],"abstract":["Severe COVID-19 associated pneumonia patients may exhibit features of systemic hyper-inflammation designated under the umbrella term of macrophage activation syndrome (MAS) or cytokine storm, also known as secondary haemophagocytic lymphohistocytosis (sHLH). This is distinct from HLH associated with immunodeficiency states termed primary HLH -with radically different therapy strategies in both situations. COVID-19 infection with MAS typically occurs in subjects with adult respiratory distress syndrome (ARDS) and historically, non-survival in ARDS was linked to sustained IL-6 and IL-1 elevation. We provide a model for the classification of MAS to stratify the MAS-like presentation in COVID-19 pneumonia and explore the complexities of discerning ARDS from MAS. We describe the potential impact of viral load and therapy timing towards improving the outcome of IL-6 antagonism and other immunomodulatory therapies."],"journal":"Autoimmun Rev","authors":["McGonagle, Dennis","Sharif, Kassem","O'Regan, Anthony","Bridgewood, Charlie"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32251717","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.autrev.2020.102537","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1663352136284504064,"score":47.19613},{"pmid":32275971,"title":"COVID-19 in patients with diabetes: risk factors that increase morbidity.","text":["COVID-19 in patients with diabetes: risk factors that increase morbidity.","Metabolism","Klonoff, David C","Umpierrez, Guillermo E","32275971"],"journal":"Metabolism","authors":["Klonoff, David C","Umpierrez, Guillermo E"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275971","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.metabol.2020.154224","keywords":["COVID-19","Corticosteroid","Diabetes","Risk","Telemedicine"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663712077896744962,"score":47.018093}]}